Association of single nucleotide polymorphism in hsa-miR-499 and hsa-miR-196a2 with the risk of prostate cancer
- 22 Downloads
Prostate cancer (PCa) is one the most common malignant cancers in men. Micro-RNAs are a group of a noncoding small molecule, which plays critical roles in signalling pathways, metabolism, apoptosis and cancer development. The purpose of this study was to examine the possible association between the hsa-miR-499 (rs3746444) and hsa-miR-196a2 (rs11614913) gene polymorphisms with the risk of PCa.
The case–control investigation was performed on 300 peripheral blood samples, consisting of 150 patients with PCa and 150 healthy men without a family history of cancers. Genetic variations of hsa-miR-499 and hsa-miR-196a2 genes were assessed using the PCR–RFLP method.
The T/T + TC/CC genotype frequencies showed a significant association between has-mir499 (rs3746444 T>C) gene polymorphism with the risk of PCa (p = 0.027; OR 1.780; 95% CI 1.030–3.113). The genotype frequencies of hsa-miR-196a2 gene did not reveal a statistically significant difference between two groups (p > 0.05).
Our findings supported that hsa-miR-499 gene polymorphism significantly increased susceptibility to PCa and may be considered as a potential prognostic biomarker in PCa patients. The findings suggested that no correlation between hsa-miR-196a2 gene polymorphism and PCa susceptibility in an Iranian population.
KeywordsProstate cancer Prognostic biomarker Hsa-miR-499 Hsa-miR-196a
This article was extracted from an MSc thesis (IR. 951010) at Ahar Branch Islamic Azad University. We would like to appreciate all the staffs of Imam Khomeini Hospital and medical University of Tehran.
Compliance with ethical standards
Conflict of interest
Ramin Nouri and Saeid Ghorbian declare that no conflict of interest.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
Informed consent was obtained from all individual participants included in the study.
- 2.Gavin AT, Donnelly D, Donnelly C, Drummond FJ, Morgan E, Gormley GJ et al (2016) Effect of investigation intensity and treatment differences on prostate cancer survivor’s physical symptoms, psychological well-being and health-related quality of life: a two country cross-sectional study. BMJ Open 6(12):e012952CrossRefGoogle Scholar
- 4.Rennert H, Zeigler-Johnson CM, Addya K, Finley MJ, Walker AH, Spangler E et al (2005) Association of susceptibility alleles in ELAC2/HPC2, RNASEL/HPC1, and MSR1 with prostate cancer severity in European American and African American men. Cancer Epidemiol Biomark Prev 14(4):949–957CrossRefGoogle Scholar
- 6.Kian R, Moradi S, Ghorbian S (2018) Role of components of microRNA machinery in carcinogenesis. Exp Oncol 40(1):2–9Google Scholar
- 9.Fazli M, Ghorbian S (2018) Association study of non-coding RNA miR-499 and miR196a2 gene polymorphisms with the risk of idiopathic recurrent pregnancy loss. Gene Cell Tissue 5(1):e67253Google Scholar
- 19.Greco F, Inferrera A, La Rocca R, Navarra M, Casciaro M, Grosso G et al (2018) The potential role of MicroRNAs as biomarkers in benign prostatic hyperplasia: a systematic review and meta-analysis. Eur Urol Focus 4569(18):30009–30009Google Scholar